RetinalGenix Technologies annual stock-based compensation
2020
2021
2022
2023
2024
2025
RetinalGenix Technologies Stock-Based Compensation Growth & History (RTGN)
RetinalGenix Technologies's stock-based compensation was $1.0M for fiscal 2025.
View full RetinalGenix Technologies company overviewRetinalGenix Technologies annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.0M | −$1.6M | −60.13% |
| 2024 | 2024-12-31 | $2.6M | $1.9M | +292.92% |
| 2023 | 2023-12-31 | $664,208 | $404,908 | +156.15% |
| 2022 | 2022-12-31 | $259,300 | −$48,618 | −15.79% |
| 2021 | 2021-12-31 | $307,918 | $87,712 | +39.83% |
| 2020 | 2020-12-31 | $220,206 | — | — |
RetinalGenix Technologies quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $24,782 | −$225,407 | −90.09% |
| Q1 2026 | 2026-03-31 | $210,016 | −$21,917 | −9.45% |
| Q4 2025 | 2025-12-31 | $281,246 | −$88,441 | −23.92% |
| Q3 2025 | 2025-09-30 | $277,226 | −$19,030 | −6.42% |
| Q2 2025 | 2025-06-30 | $250,189 | $39,180 | +18.57% |
| Q1 2025 | 2025-03-31 | $231,933 | −$1.5M | −86.62% |
| Q4 2024 | 2024-12-31 | $369,687 | $291,180 | +370.90% |
| Q3 2024 | 2024-09-30 | $296,256 | −$132,427 | −30.89% |
| Q2 2024 | 2024-06-30 | $211,009 | $132,500 | +168.77% |
| Q1 2024 | 2024-03-31 | $1.7M | $1.7M | +2107.18% |
| Q4 2023 | 2023-12-31 | $78,507 | −$2 | −0.00% |
| Q3 2023 | 2023-09-30 | $428,683 | $357,994 | +506.44% |
| Q2 2023 | 2023-06-30 | $78,509 | $23,458 | +42.61% |
| Q1 2023 | 2023-03-31 | $78,509 | $23,458 | +42.61% |
| Q4 2022 | 2022-12-31 | $78,509 | $23,458 | +42.61% |
| Q3 2022 | 2022-09-30 | $70,689 | $15,638 | +28.41% |
| Q2 2022 | 2022-06-30 | $55,051 | −$31,278 | −36.23% |
| Q1 2022 | 2022-03-31 | $55,051 | −$56,436 | −50.62% |
| Q4 2021 | 2021-12-31 | $55,051 | — | — |
| Q3 2021 | 2021-09-30 | $55,051 | $0 | 0.00% |
| Q2 2021 | 2021-06-30 | $86,329 | — | — |
| Q1 2021 | 2021-03-31 | $111,487 | — | — |
| Q3 2020 | 2020-09-30 | $55,051 | — | — |
RetinalGenix Technologies stock-based compensation trends
Over the last five fiscal years, RetinalGenix Technologies's stock-based compensation increased from $220,206 to $1.0M, a change of $820,388. The latest reported quarter, Q2 2026, shows $24,782.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RetinalGenix Technologies source filings ↗